Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Degenkolbe

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2014
MiR-497∼195 cluster microRNAs regulate osteoblast differentiation by targeting BMP signalingJohannes Grünhagen, Raghu Bhushan, Elisa Degenkolbe, et al.
Cancers|November 26, 2022
The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment LandscapeChristian Doehn, Martin Bögemann, Viktor Grünwald, et al.
Bone|December 28, 2014
Improved bone defect healing by a superagonistic GDF5 variant derived from a patient with multiple synostoses syndromeElisa Degenkolbe, Carolin Schwarz, Claus-Eric Ott, et al.
Plos Genetics|October 8, 2013
A GDF5 point mutation strikes twice--causing BDA1 and SYNS2Elisa Degenkolbe, Jana König, Julia Zimmer, et al.
Cancer Research|June 24, 2011
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patientsRalph Tiedt, Elisa Degenkolbe, Pascal Furet, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2014
MiR-497∼195 cluster microRNAs regulate osteoblast differentiation by targeting BMP signalingJohannes Grünhagen, Raghu Bhushan, Elisa Degenkolbe, et al.
Cancers|November 26, 2022
The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment LandscapeChristian Doehn, Martin Bögemann, Viktor Grünwald, et al.
Bone|December 28, 2014
Improved bone defect healing by a superagonistic GDF5 variant derived from a patient with multiple synostoses syndromeElisa Degenkolbe, Carolin Schwarz, Claus-Eric Ott, et al.
Plos Genetics|October 8, 2013
A GDF5 point mutation strikes twice--causing BDA1 and SYNS2Elisa Degenkolbe, Jana König, Julia Zimmer, et al.
Cancer Research|June 24, 2011
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patientsRalph Tiedt, Elisa Degenkolbe, Pascal Furet, et al.
Pageof 1